A
Alcista
Alcista · 25%PVLA
$34.32
Precio del escenario
$125.100
-1.276 (-1.02%)Al cierre
Loading chart…
- Máximo
- 125.930
- Apertura
- 124.600
- Precio medio ponderado por volumen
- 124.12
- Volumen
- 164.22K
- Capitalización
- —
- Mínimo
- 121.340
- Importe
- 20.38M
- EV/EBITDA, TTM
- 0.00
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Análisis de IA of Palvella Therapeutics Inc (PVLA)
MantenerPalvella Therapeutics is not a good buy right now due to its current price of $125.1, which is significantly below the analyst price targets of $240 and $246. However, the stock has a low RSI of 42.86, indicating it is nearing oversold territory, which could present a buying opportunity in the future. The main risk is the negative earnings trend, with a reported EPS of -1.52, missing estimates by $0.34, which raises concerns about profitability and investor confidence.
Métricas de valoración
El PER previsto actual de Palvella Therapeutics Inc (PVLA) es 0.00, frente a su media de 5 años de -12.97.
Escenarios de precio de Alphio AI para PVLA
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con PVLA en cartera
Cronología de eventos
Noticias
9.010-15NewsfilterPalvella Reports New Developments on QTORIN™ Therapy
- 1.010-13Newsfilter
Palvella Therapeutics to Participate in Healthcare Conference
- 8.510-12Newsfilter
Palvella Reports SELVA Study Findings on QTORIN™ Rapamycin
- 5.009-09Newsfilter
Palvella Appoints New Chief Medical Officer to Advance Rare Skin Disease Therapies
- 8.508-31Newsfilter
QTORIN™ Rapamycin Seeks FDA Approval for Rare Disease Treatment
Preguntas frecuentes sobre PVLA, respondidas por Alphio AI
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations. It operates in the Healthcare sector.
Palvella Therapeutics is not a good buy right now due to its current price of $125.1, which is significantly below the analyst price targets of $240 and $246. However, the stock has a low RSI of 42.86, indicating it is nearing oversold territory, which could present a buying opportunity in the future. The main risk is the negative earnings trend, with a reported EPS of -1.52, missing estimates by $0.34, which raises concerns about profitability and investor confidence.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.